We found that MLN4924 showed a therapeutic efficiency on murine IBD model in vivo and suppressed DCs maturation in vitro via inactivating mTOR signaling pathway, which provide a new opportunity on IBD therapy. Here, MTOR is linked to inflammatory bowel disease.